首页> 美国卫生研究院文献>Journal of Child and Adolescent Psychopharmacology >Cefdinir for Recent-Onset Pediatric Neuropsychiatric Disorders: A Pilot Randomized Trial
【2h】

Cefdinir for Recent-Onset Pediatric Neuropsychiatric Disorders: A Pilot Randomized Trial

机译:头孢地尼用于近期发作的小儿神经精神疾病:一项随机试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objective: Previous studies suggest that the unexplained sudden and severe onset of obsessive-compulsive disorder (OCD) and/or tics may be infection or immune precipitated. Beta lactam antibiotics may be neuroprotective beyond their antimicrobial efficacy. We examine the preliminary safety and efficacy of cefdinir in reducing obsessive-compulsive and/or tic severity in children with new-onset symptoms.>Method: Twenty subjects were randomized to receive placebo or cefdinir for 30 days for the treatment of recent-onset OCD and/or tics. The placebo group received a comparable inactive treatment matched for taste, color, and consistency. The Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) and Yale Global Tic Severity Scale (YGTSS) were the primary outcome measures utilized.>Results: Subjects receiving cefdinir saw notable improvements in tic symptoms, with 44.4% showing at least a 25% reduction in YGTSS (mean decrease=9.5) scores compared with 9.1% of the placebo group (mean decrease=0.13). Despite improvements, significant group differences were not observed for YGTSS (F [1, 13]=4.03, p=0.066) although there were moderate differences between group treatment effects (d=0.72). For OCD symptoms, subjects receiving cefdinir saw improvements in OCD symptoms, with 33.3% showing at least a 25% reduction in CY-BOCS scores (mean decrease=7.8) compared with 27.3% of the placebo group (mean decrease=4.7), but there were also no significant differences for CY-BOCS (F [1, 13]=0.385, p=0.546; d=0.24).>Conclusions: Subjects assigned to cefdinir exhibited notable, albeit nonstatistically significant, improvements in tic symptoms, compared with the placebo group. There were also some improvements in OCD symptoms, although these were not significant. Overall, cefdinir was well tolerated. Given these preliminary results, a fully powered study is warranted to explore the efficacy of cefdinir as a therapeutic tool for new-onset pediatric neuropsychiatric symptoms, particularly those that appear to be precipitated by infection.
机译:>目的:先前的研究表明,无法解释的强迫症(OCD)和/或抽动症的突然和严重发作可能是感染或免疫沉淀。 β-内酰胺类抗生素可能超出其抗菌功效而具有神经保护作用。我们研究了头孢地尼降低新发症状儿童强迫症和/或抽动的严重程度的初步安全性和有效性。>方法:将20名受试者随机分为30天接受安慰剂或头孢地尼治疗最近发作的强迫症和/或抽动的治疗。安慰剂组接受了可比的无味治疗,其口味,颜色和稠度匹配。儿童的耶鲁-布朗强迫症量表(CY-BOCS)和耶鲁全球抽动严重度表(YGTSS)是主要的结局指标。>结果:接受头孢地尼治疗的受试者的抽动症状明显改善, 44.4%的人表示YGTSS得分降低了至少25%(平均降低= 9.5),而安慰剂组为9.1%(平均降低= 0.13)。尽管有所改善,尽管各组治疗效果之间存在中等差异(d = 0.72),但YGTSS并未观察到显着的组差异(F [1,13] = 4.03,p = 0.066)。对于OCD症状,接受头孢地尼的受试者的OCD症状有所改善,其中33.3%的患者的CY-BOCS评分至少降低了25%(平均降低= 7.8),而安慰剂组为27.3%(平均降低= 4.7),但是CY-BOCS也没有显着差异(F [1,13] = 0.385,p = 0.546; d = 0.24)。>结论:分配给头孢地尼的受试者表现出显着的改善,尽管无统计学意义抽搐症状的患者,与安慰剂组相比。强迫症的症状也有所改善,尽管并不明显。总体而言,头孢地尼的耐受性良好。鉴于这些初步结果,有必要进行一项有力的研究,以探讨头孢地尼作为新发小儿神经精神病症状(尤其是那些似乎是由感染引起的症状)的治疗工具的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号